Associations - DNMT3A mutation

DNMT3A mutation DNMT3A mutation	Myelodysplastic Syndrome MDS	DNMT3A mutation DNMT3A mutation	Myelodysplastic Syndrome MDS	RVU120 Sensitive: C4 – Case Studies EHA 2022 - 4 days (NewC4)	RVU120 Sensitive: C4 – Case Studies EHA 2022 - 4 days - (New C4)
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	azacitidine Resistant: B - Late Trials	azacitidine Resistant: B - Late Trials
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	venetoclax + midostaurin Resistant: C3 – Early Trials	venetoclax + midostaurin Resistant: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Myelodysplastic Syndrome MDS	DNMT3A mutation DNMT3A mutation	Myelodysplastic Syndrome MDS	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	cytarabine Resistant: C3 – Early Trials	cytarabine Resistant: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	venetoclax Sensitive: C3 – Early Trials	venetoclax Sensitive: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	venetoclax + gilteritinib Resistant: C3 – Early Trials	venetoclax + gilteritinib Resistant: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	venetoclax + sorafenib Resistant: C3 – Early Trials	venetoclax + sorafenib Resistant: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Myelodysplastic Syndrome MDS	DNMT3A mutation DNMT3A mutation	Myelodysplastic Syndrome MDS	azacitidine Resistant: C3 – Early Trials	azacitidine Resistant: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Myelodysplastic Syndrome MDS	DNMT3A mutation DNMT3A mutation	Myelodysplastic Syndrome MDS	decitabine Resistant: C3 – Early Trials	decitabine Resistant: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	quizartinib Sensitive: C3 – Early Trials	quizartinib Sensitive: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Chronic Myeloid Leukemia CML	DNMT3A mutation DNMT3A mutation	Chronic Myeloid Leukemia CML	YD312 Resistant: C3 – Early Trials	YD312 Resistant: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	decitabine/cedazuridine Sensitive: C3 – Early Trials	decitabine / cedazuridine Sensitive: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Colorectal Cancer CRC	DNMT3A mutation DNMT3A mutation	Colorectal Cancer CRC	sintilimab + fruquintinib Resistant: C3 – Early Trials	sintilimab + fruquintinib Resistant: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	T Cell Non-Hodgkin Lymphoma T Cell Non-Hodgkin Lymphoma	DNMT3A mutation DNMT3A mutation	T Cell Non-Hodgkin Lymphoma T Cell Non-Hodgkin Lymphoma	lenalidomide Resistant: C3 – Early Trials	lenalidomide Resistant: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Non Small Cell Lung Cancer NSCLC	DNMT3A mutation DNMT3A mutation	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Sensitive: C3 – Early Trials	PD-L1 inhibitor Sensitive: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	DCAG Sensitive: C3 – Early Trials	DCAG Sensitive: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	RVU120 Sensitive: C3 – Early Trials	RVU120 Sensitive: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	DNMT3A mutation DNMT3A mutation	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	CHOP Resistant: C3 – Early Trials	CHOP Resistant: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	EPZ-5676 Sensitive: D – Preclinical	EPZ-5676 Sensitive: D – Preclinical
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	ABBV-744 Sensitive: D – Preclinical	ABBV-744 Sensitive: D – Preclinical